1
|
Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SA. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplant 2013; 48:947-52. [PMID: 23334272 PMCID: PMC3638062 DOI: 10.1038/bmt.2012.276] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2012] [Revised: 12/04/2012] [Accepted: 12/05/2012] [Indexed: 11/17/2022]
Abstract
Increasing treatment intensity has improved outcomes for children with neuroblastoma. We performed a pilot study in the Children’s Oncology Group (COG) to assess feasibility and toxicity of a tandem myeloablative regimen without total body irradiation (TBI) supported by autologous CD34 selected peripheral blood stem cells. Forty-one patients with high-risk neuroblastoma were enrolled; eight patients did not receive any myeloablative consolidation procedure, and seven received only one. Two patients out of 41 (4.9%) experienced transplant-related mortality. CD34 selection was discontinued after subjects were enrolled due to serious viral illness. From the time of study enrollment, the overall 3-year event-free survival (EFS) and overall survival (OS) were 44.8±9.6% and 59.2±9.2% (N=41). These results demonstrate that tandem transplantation in the cooperative group setting is feasible and support a randomized comparison of single versus tandem myeloablative consolidation with PBSC support for high-risk neuroblastoma.
Collapse
Affiliation(s)
- A E Seif
- Department of Pediatrics, Division of Oncology, The Children's Hospital of Philadelphia and Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA 19104, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Bagatell R, Wagner LM, Cohn SL, Maris JM, Reynolds CP, Stewart CF, Voss SD, Gelfand M, Kretschmar CS, London WB. Irinotecan plus temozolomide in children with recurrent or refractory neuroblastoma: A phase II Children's Oncology Group study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10011 Background: Treatment of children with relapsed or refractory neuroblastoma (NB) remains a challenge. Responses to irinotecan (IRN) + temozolomide (TEM) were seen in NB xenograft-bearing mice, and objective responses were observed in patients with NB treated on a phase I study of this combination. Methods: A phase II study of IRN (10 mg/m2/dose IV daily × 5 days times; 2 weeks) + TEM (100 mg/m2/dose PO daily × 5 days) for children with relapsed or refractory NB was conducted. A one-stage design (endpoint: best overall response) required 5 or more responders out of the first 25 evaluable patients on each of two strata: 1) patients with disease measurable by CT or MRI; and 2) patients with disease detected only by bone marrow aspirate/biopsy and/or MIBG scan. Patients with stable disease or better after 3 cycles could receive an additional 3 cycles of study therapy. International Neuroblastoma Response Criteria were used for response assessment. Radiographic responses were centrally reviewed. Results: Fifty-five eligible and evaluable patients were enrolled, 28 on stratum 1 and 27 on stratum 2. Four responses were observed in the first 25 evaluable stratum 1 patients, and five responses were observed in the first 25 evaluable stratum 2 patients. Three patients had complete responses, but the overall objective response rate (CR+PR) was 16% (9/55). Eleven (stratum 1) and 13 (stratum 2) patients had stable disease. Less than 5% of patients experienced Grade 3 or 4 diarrhea. Although 18% of patients on stratum 1 and 35% of patients on stratum 2 experienced Grade 3 or 4 neutropenia during the first 3 cycles of therapy, <10% of all patients developed evidence of infection while neutropenic. Thrombocytopenia (Grade 3 or 4) was observed in only 7% of patients on stratum 1 and 12% on stratum 2. Conclusions: The combination of IRN+TEM was well tolerated in patients with recurrent or refractory NB. There were 9 objective responses, including 3 complete responses. The minimum desired response rate was attained within stratum 2, but not stratum 1. IRN+TEM may be an appropriate backbone for further study in the relapse setting in combination with novel, targeted agents. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. Bagatell
- Children's Hospital of Philadelphia, Philadelphia, PA; Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Chicago, Chicago, IL; Texas Tech UHSC, Lubbock, TX; St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital Boston, Boston, MA; Boston Floating Hospital for Infants and Children, Boston, MA; University of Florida, Gainesville, FL
| | - L. M. Wagner
- Children's Hospital of Philadelphia, Philadelphia, PA; Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Chicago, Chicago, IL; Texas Tech UHSC, Lubbock, TX; St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital Boston, Boston, MA; Boston Floating Hospital for Infants and Children, Boston, MA; University of Florida, Gainesville, FL
| | - S. L. Cohn
- Children's Hospital of Philadelphia, Philadelphia, PA; Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Chicago, Chicago, IL; Texas Tech UHSC, Lubbock, TX; St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital Boston, Boston, MA; Boston Floating Hospital for Infants and Children, Boston, MA; University of Florida, Gainesville, FL
| | - J. M. Maris
- Children's Hospital of Philadelphia, Philadelphia, PA; Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Chicago, Chicago, IL; Texas Tech UHSC, Lubbock, TX; St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital Boston, Boston, MA; Boston Floating Hospital for Infants and Children, Boston, MA; University of Florida, Gainesville, FL
| | - C. P. Reynolds
- Children's Hospital of Philadelphia, Philadelphia, PA; Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Chicago, Chicago, IL; Texas Tech UHSC, Lubbock, TX; St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital Boston, Boston, MA; Boston Floating Hospital for Infants and Children, Boston, MA; University of Florida, Gainesville, FL
| | - C. F. Stewart
- Children's Hospital of Philadelphia, Philadelphia, PA; Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Chicago, Chicago, IL; Texas Tech UHSC, Lubbock, TX; St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital Boston, Boston, MA; Boston Floating Hospital for Infants and Children, Boston, MA; University of Florida, Gainesville, FL
| | - S. D. Voss
- Children's Hospital of Philadelphia, Philadelphia, PA; Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Chicago, Chicago, IL; Texas Tech UHSC, Lubbock, TX; St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital Boston, Boston, MA; Boston Floating Hospital for Infants and Children, Boston, MA; University of Florida, Gainesville, FL
| | - M. Gelfand
- Children's Hospital of Philadelphia, Philadelphia, PA; Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Chicago, Chicago, IL; Texas Tech UHSC, Lubbock, TX; St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital Boston, Boston, MA; Boston Floating Hospital for Infants and Children, Boston, MA; University of Florida, Gainesville, FL
| | - C. S. Kretschmar
- Children's Hospital of Philadelphia, Philadelphia, PA; Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Chicago, Chicago, IL; Texas Tech UHSC, Lubbock, TX; St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital Boston, Boston, MA; Boston Floating Hospital for Infants and Children, Boston, MA; University of Florida, Gainesville, FL
| | - W. B. London
- Children's Hospital of Philadelphia, Philadelphia, PA; Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Chicago, Chicago, IL; Texas Tech UHSC, Lubbock, TX; St. Jude Children's Research Hospital, Memphis, TN; Children's Hospital Boston, Boston, MA; Boston Floating Hospital for Infants and Children, Boston, MA; University of Florida, Gainesville, FL
| |
Collapse
|
5
|
Abstract
PURPOSE Desmoplastic round cell tumor (DSCT) is a highly malignant abdominal tumor first described in 1991, with subsequent cases predominantly noted in pathologic case reports. The authors evaluated response to alternating, intensive chemotherapy in three patients with DSCT, and reviewed the clinical experience with this newly described tumor as reported in the literature. PATIENTS AND METHODS Three adolescent boys with DSCT were treated intravenously with vincristine 2 mg/m2, doxorubicin 75 mg/m2, cyclophosphamide 1.8 g/m2, alternating with 5-day cycles of etoposide 100 mg/m2/day, ifosfamide 1.8 g/m2/day for a total of 11-15 courses. RESULTS Each patient showed initial tumor regression during chemotherapy, but developed progressive disease within 8-18 months. One patient subsequently showed a transient response to doxorubicin 45 mg/m2 plus 5-fluorouracil 500-600 mg/m2. All three patients died of disease within 20 months of diagnosis. A comprehensive literature review of clinical data on 101 reported cases of DSCT is presented. The median age was 21 years (range 6-38 years) with 78 male patients and 23 female patients. Ninety-nine cases involved tumor mass in the abdominal-pelvic cavity in proximity to the mesentery. Metastatic seeding to the omentum was most common, followed by spread of disease to liver, distant lymph nodes, lung, and occasionally to scrotum or to ovary. Tumor response to chemotherapy was noted in approximately 50% of 40 patients who received combinations of doxorubicin, cisplatin, cyclophosphamide, etoposide, and/or 5-fluorouracil. Four of 13 patients who received additional radiotherapy were alive at 24-48 months. Median survival was 17 months (range: 3-72 months), with only two patients reported disease free beyond 2 years at 40 and 48 months. CONCLUSION DSCT should be included in the differential diagnosis of small round cell tumors in children and young adults. Tumor regression has been noted during multiagent chemotherapy, but prolonged survival is rare with current therapies.
Collapse
Affiliation(s)
- C S Kretschmar
- Division of Hematology-Oncology, Department of Pediatrics, Floating Hospital for Children at the New England Medical Center, Boston, Massachusetts 02111, USA
| | | | | | | |
Collapse
|
9
|
Crombleholme TM, Harris BH, Jacir NN, Latchaw LA, Kretschmar CS, Rosenfield CG, Wolfe LC, Cendron M, Trask C, Wolfe HJ. The desmoplastic round cell tumor: a new solid tumor of childhood. J Pediatr Surg 1993; 28:1023-5. [PMID: 8229589 DOI: 10.1016/0022-3468(93)90508-i] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Three patients with a new, pathologically distinct solid tumor of childhood have been treated recently. The disease is characterized by male predominance, adolescent onset, an extensive abdominal primary tumor, and aggressive metastases to regional lymph nodes, liver, and lung. Two patients presented with vague abdominal pain and the third with testicular pain. All three noted fatigue and malaise of less than two months' duration with minimal associated weight loss. Computed tomography (CT) scans of the abdomen and chest were obtained for initial preoperative staging, and then all three underwent surgical exploration. Widespread disease was found in each case. In no instance was complete tumor extirpation possible because of extensive peritoneal spread and lymphatic and hepatic metastases. Histologically, all three tumors consisted of round blue cells with a dense desmoplastic reaction and focal rhabdoid features. Immunohistochemical markers for epithelial, neural, and muscle elements were positive. Aggressive multidrug chemotherapeutic regimens were used in each case, and all three patients are alive and well but with known residual disease. We conclude that in cases of the desmoplastic round cell tumor of childhood, CT scans underestimate the extent of disease, and exploratory laparotomy is necessary for diagnosis and appropriate staging. Surgery is usually palliative because of extensive spread. Awareness of this newly recognized aggressive solid tumor of childhood is essential to define its natural history and guide the development of effective multidisciplinary therapeutic regimens.
Collapse
Affiliation(s)
- T M Crombleholme
- Department of Pediatric Surgery, Tufts University School of Medicine, Boston, MA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Kretschmar CS, Tarbell NJ, Kupsky W, Lavally BL, Loeffler JS, Wolfe L, Strand R, Scott RM, Sallan SE. Pre-irradiation chemotherapy for infants and children with medulloblastoma: a preliminary report. J Neurosurg 1989; 71:820-5. [PMID: 2585072 DOI: 10.3171/jns.1989.71.6.0820] [Citation(s) in RCA: 32] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
From March, 1984, through June, 1987, 21 newly diagnosed children with high-risk medulloblastoma (Chang Stage T3 to T4) were treated on a 9-week postoperative, pre-irradiation chemotherapy regimen consisting of vincristine and cisplatin. The children over 2 years old then received radiation therapy. Six infants (aged 6 to 18 months) were maintained on chemotherapy consisting of MOP (nitrogen mustard, vincristine, and procarbazine) until the age of 2 years, at which time they were referred for irradiation. Of 13 children with measurable disease following surgery, five showed a definite response on computerized tomography scans to vincristine and cisplatin (one complete response and four partial responses) and five others showed clear marginal responses. Four of the six infants were disease-free at 19, 32, 35, and 57 months from diagnosis. One infant developed progressive disease at the completion of the vincristine and cisplatin course, and a second infant had progression during MOP administration. Three of the 21 children developed hearing loss within the speech frequencies during cisplatin treatments, but there were no other major toxicities. Fifteen children remained disease-free with a median follow-up period of 35 months (range 19 to 57 months). Chemotherapy given between surgery and radiotherapy may allow for the direct evaluation of a specific drug regimen and permit the postponement of radiation therapy in infants. Pre-irradiation vincristine and cisplatin was well tolerated and effective in shrinking the tumor in most children with medulloblastoma. Such chemotherapy regimens have the potential for extending long-term survival in high-risk children.
Collapse
Affiliation(s)
- C S Kretschmar
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | | | | | | | | | | | | | | | | |
Collapse
|